Danqing (Angela) Yin is a PhD candidate in Bioinformatics at the University of Hong Kong, bringing a unique interdisciplinary background that combines her Bachelor of Biomedicine (University of Melbourne) and Master of IT (University of Sydney). Her research focuses on leveraging cloud computing and artificial intelligence to tackle complex challenges in single-cell omics and genomic data analysis. Throughout her journey, Angela has made significant contributions to cloud architecture and software development for large-scale genomic projects at prestigious Australian research institutes, including the Walter and Eliza Hall Institute of Medical Research, Garvan Institute of Medical Research, and Hudson Institute. 

Angela’s work seamlessly bridges academia and industry. She played a pivotal role in the successful commercialization of genomic sequencing analyses for rare diseases through Genome.One, a spin-off backed by the Garvan Institute with 16 Million AUD in funding. Currently, Angela is expanding her entrepreneurial pursuits in the field of AI-driven drug discovery. She has co-founded a startup with fellow PhD candidates from the University of Cambridge, David Baker’s lab, and University of Hong Kong. This venture has recently been accepted into the Hong Kong Science and Technology Park incubator program, where she managed securing 15 million HKD funding over four years.

As a visiting scholar at the Huang Lab at the Broad Institute, Angela is applying cutting-edge deep learning methods to identify and explain causal genetic variants associated with schizophrenia. This project aims to integrate multi-omics data and enhance the interpretability of AI models in psychiatric genetics. Her work has the potential to significantly advance our understanding of the genetic basis of Schizophrenia and inform new therapeutic strategies. Angela’s research exemplifies the power of interdisciplinary approaches in modern bioinformatics, combining expertise in genomics, software engineering, and artificial intelligence to drive innovation in both academic research and commercial applications.